Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6873286

N=C(N)c1ccc(CCC(=O)O)c(OCCNC(=O)C2CCN(Cc3ccncc3)CC2)c1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
F10 P00742 10/20 0.75
F2 P00734 4/20 0.47
TMPRSS15 P98073 3/20 0.45
CHRM4 P08173 3/20 0.41
ITGB3 P05106 2/20 0.41
ITGA2B P08514 2/20 0.41
ACKR3 P25106 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6874356 0.89 F10 (0.78) F10F2TMPRSS15ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6870518 0.89 F10 (0.94) F10F2TMPRSS15ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6870923 0.87 F10 (0.90) F10TMPRSS15ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6870032 0.86 F10 (0.77) F10F2TMPRSS15ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6873650 0.84 F10 (0.72) F10F2TMPRSS15ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6871129 0.83 F10 (0.70) F10F2TMPRSS15CHRM4ITGB3
Trifluoroacetic Acid SCHEMBL6872129 0.82 F10 (0.69) F10F2TMPRSS15ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6870919 0.82 F10 (0.71) F10F2TMPRSS15ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6873052 0.82 F10 (0.80) F10TMPRSS15ITGB3ITGA2B
Trifluoroacetic Acid SCHEMBL6864661 0.81 F10 (0.79) F10TMPRSS15ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812231-B2 INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X AJINOMOTO CO., INC. (JP) 2004-11-02 US disclosed
US-20020107290-A1 Benzamidine derivative AJINOMOTO CO., INC. (JP) 2002-08-08 US disclosed
US-6410538-B2 ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI AJINOMOTO CO., INC. (JP) 2002-06-25 US disclosed
US-20010056123-A1 Anticoagulant or an agent for treating or preventing thrombi or emboli AJINOMOTO CO., INC (JP) 2001-12-27 US disclosed
EP-1086946-A1 BENZAMIDINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107290-A1 Benzamidine derivative SERPINE1, SERPINC1, TFPI F10 21/4885F2 6/4885TMPRSS15 276/4885
US-20010056123-A1 Anticoagulant or an agent for treating or preventing thrombi or emboli SERPINC1, SERPINE1, F2 F10 16/4885F2 3/4885TMPRSS15 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.